DR. JOSEPH HABBOUSHE, M.D.
Osteopathic Medicine at 1 Ave, New York, NY
License number
New York 257251-1
Category
Osteopathic Medicine
Type
Emergency Medicine
Address
Address
281 1St Ave, New York, NY 10003
Phone
(212) 420-2847
Personal information
See more information about JOSEPH HABBOUSHE at radaris.comName
Address
Phone
93 4Th Ave #19, New York, NY 10003
Professional information
Joseph Habboushe, New York NY
Specialties:
Emergency Medicine Physician
Address:
281 1St Ave, New York, NY 10003
Dr. Joseph Habboushe, New York NY - MD (Doctor of Medicine)
Specialties:
Emergency Medicine
Address:
281 1St Ave, New York 10003
(212) 420-2847 (Phone)
(212) 420-2847 (Phone)
Certifications:
Emergency Medicine, 2011
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Weill Cornell Medical College
Graduated: 2006
Weill Cornell Medical College
Graduated: 2006
Joseph Habboushe
Location:
Greater New York City Area
Industry:
Hospital & Health Care
Joseph Habboushe
Location:
Greater New York City Area
Industry:
Hospital & Health Care
Combination Tablet With Chewable Outer Layer
US Patent:
2013018, Jul 25, 2013
Filed:
Dec 19, 2012
Appl. No.:
13/720723
Inventors:
Vitalis LLC - Wilmington DE, US
Joseph Habboushe - New York NY, US
Joseph Habboushe - New York NY, US
Assignee:
Vitalis LLC - Wilmington DE
International Classification:
A61K 31/455, A61K 9/28, A61K 9/20, A61K 31/616
US Classification:
424468, 514161
Abstract:
A pharmaceutical composition in the form of a combination tablet is described. The tablet has a rapidly absorbed component that enters the circulation by traversing the buccal mucosa, oral mucosa and combinations thereof, and a more slowly absorbed component that is swallowed. The therapeutic agent in the swallowed portion is absorbed across the gastric mucosa. The combination tablet may be modified, by varying the specific combinations of excipients, fillers, and the like to effect distinct release rates. In addition, the rapid and slow components may have identical or different therapeutic agents depending on the application to a specific medical condition. One embodiment of the combination tablet includes a prostaglandin inhibitor in the rapidly absorbed component in order to mitigate the side effects of immediate release niacin that is in the slow absorbing component. Such combination compositions will increase patient compliance with various dosing regimens due to the resultant decrease in the number of tablets that a patient would need to take on a daily basis.
Skin Marking Device And Suture Holder
US Patent:
2010029, Nov 18, 2010
Filed:
Nov 18, 2008
Appl. No.:
12/743531
Inventors:
Kaushal Shah - Forest Hills NY, US
Joseph Habboushe - New York NY, US
Joseph Habboushe - New York NY, US
International Classification:
A61B 17/04, B05C 1/00
US Classification:
606148, 118255
Abstract:
A skin marking device can include two or more skin marking members and a holding member coupled with the two or more skin marking members. The holding member can include at least one adjustment assembly. The adjustment assembly can adjust at least one of width or length between the skin marking members. In an example, a suture holder device can include a base and a member coupled with the base. The member can include one or more suture assembly holders. At least one attachment can be coupled with the base. The attachment can be adapted to couple the suture holder device with other structure.
Anti-Flush Compositions
US Patent:
2013011, May 9, 2013
Filed:
Oct 24, 2012
Appl. No.:
13/659196
Inventors:
Vitalis LLC - Wilmington DE, US
Joseph Habboushe - New York NY, US
Joseph Habboushe - New York NY, US
Assignee:
Vitalis LLC - Wilmington DE
International Classification:
A61K 9/00, A61K 31/44, A61K 9/24, A61K 31/616
US Classification:
424472, 560 71, 514165, 514161, 424400
Abstract:
Disclosed are pharmaceutical compositions having a portion of aspirin for intraoral release and another aspirin for gastrointestinal release. The compositions can further include niacin. Methods of using such compositions to treat diseases or conditions suitably treated by niacin are also provided which result in reduced flushing.